<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02753816</url>
  </required_header>
  <id_info>
    <org_study_id>2015-154</org_study_id>
    <nct_id>NCT02753816</nct_id>
  </id_info>
  <brief_title>TXA Study in Major Burn Surgery</brief_title>
  <official_title>The Effect of Tranexamic Acid (TXA) on Blood Loss and Transfusion Rates in Burn Wound Surgery - A Randomized, Double-Blinded Placebo-Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spectrum Health Hospitals</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spectrum Health Hospitals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Major surgery can result in blood loss that can require a blood transfusion during and/or&#xD;
      after surgery. Tranexamic acid (TXA) is a medication that was first introduced in the 1960's&#xD;
      as a treatment for heavy menstrual bleeding. Over the past 20 years, it has been used and&#xD;
      studied in patients undergoing open-heart surgery, liver transplantation, and urologic&#xD;
      surgery. Investigators believe tranexamic acid may possibly decrease bleeding related to&#xD;
      major burn surgery, resulting in reduced blood loss, lower blood transfusion rates, and&#xD;
      possibly decreased hospital costs related to your stay.&#xD;
&#xD;
      In this study, prior to each surgical procedure to treat the participants burn injury, the&#xD;
      participant will receive either the drug tranexamic acid or placebo. The placebo is a liquid&#xD;
      that looks like the tranexamic acid medicine, but does not have any active ingredient in it.&#xD;
      In this study, both the tranexamic acid and the placebo are considered research.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Neither the participant nor the study doctor will choose what treatment the participant gets.&#xD;
      The participant will have an equal chance of being given the tranexamic acid or the placebo.&#xD;
      Neither the participant nor the study doctor will know which treatment the participant is&#xD;
      receiving.&#xD;
&#xD;
      The participant will receive one 1 gram dose of either tranexamic acid or placebo immediately&#xD;
      before surgery. The dose of tranexamic acid or placebo will be given in the participants vein&#xD;
      over a 10-minute period.&#xD;
&#xD;
      Information from the participants medical record related to their surgery and recovery time&#xD;
      in the hospital will be collected by medical staff assisting with this study and recorded on&#xD;
      study forms. These study forms will be labeled with the participants study number instead of&#xD;
      their name.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study enrollment and goals unable to be reached.&#xD;
  </why_stopped>
  <start_date>April 2016</start_date>
  <completion_date type="Actual">December 3, 2019</completion_date>
  <primary_completion_date type="Actual">December 3, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intraoperative Blood Loss in mL</measure>
    <time_frame>Intraoperative, average 122 minutes</time_frame>
    <description>To determine the impact of perioperative administration of Tranexamic Acid on blood loss in major burn surgeries.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood Transfusion Rates, Defined Nominally (Binary) as Having at Least One Transfusion</measure>
    <time_frame>First burn surgery to hospital discharge</time_frame>
    <description>To determine the impact of perioperative administration of Tranexamic Acid on transfusion rates in major burn surgeries.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of Tranexamic Acid on the Total Length of Hospital Admission for a Large (350 cm2) Burn Injury</measure>
    <time_frame>Hospital admission to hospital discharge</time_frame>
    <description>To determine the impact of Tranexamic Acid on total hospital length of stay by comparing the hospital admission date and the hospital discharge date. This determination will take into account current burn size and location, procedures performed and their effect on wound healing and skin graft survival.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Tranexamic Acid</condition>
  <condition>Burn</condition>
  <condition>Major Surgery</condition>
  <arm_group>
    <arm_group_label>Tranexamic Acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 gram of Tranexamic Acid given over 10 minutes into the vein once prior to surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo given over 10 minutes into the vein once prior to surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <arm_group_label>Tranexamic Acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Comparator</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects undergoing burn excision surgery for standard of care purposes (to include:&#xD;
             greater than or equal to 350 cm2 of full thickness or deep partial thickness burns)&#xD;
&#xD;
          -  Male or female &gt; 18 years of age&#xD;
&#xD;
          -  Subject or subject's medical decision maker agrees to participate in this study and&#xD;
             provides informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with a history of hypercoagulopathy, deep vein thrombosis (DVT), pulmonary&#xD;
             embolism&#xD;
&#xD;
          -  Baseline creatinine level greater than 2.83 mg/dL&#xD;
&#xD;
          -  Subjects with known hypersensitivity to tranexamic acid&#xD;
&#xD;
          -  Patients with acquired defective color vision&#xD;
&#xD;
          -  Patients with subarachnoid hemorrhage&#xD;
&#xD;
          -  Children&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Prisoners&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth Steensma, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Spectrum Health Hospitals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Spectrum Health Hospital</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Engrav LH, Heimbach DM, Reus JL, Harnar TJ, Marvin JA. Early excision and grafting vs. nonoperative treatment of burns of indeterminant depth: a randomized prospective study. J Trauma. 1983 Nov;23(11):1001-4.</citation>
    <PMID>6355500</PMID>
  </reference>
  <reference>
    <citation>Ong YS, Samuel M, Song C. Meta-analysis of early excision of burns. Burns. 2006 Mar;32(2):145-50. Epub 2006 Jan 18. Review.</citation>
    <PMID>16414197</PMID>
  </reference>
  <reference>
    <citation>Desai MH, Herndon DN, Broemeling L, Barrow RE, Nichols RJ Jr, Rutan RL. Early burn wound excision significantly reduces blood loss. Ann Surg. 1990 Jun;211(6):753-9; discussion 759-62.</citation>
    <PMID>2357138</PMID>
  </reference>
  <reference>
    <citation>Curinga G, Jain A, Feldman M, Prosciak M, Phillips B, Milner S. Red blood cell transfusion following burn. Burns. 2011 Aug;37(5):742-52. doi: 10.1016/j.burns.2011.01.016. Epub 2011 Mar 1. Review.</citation>
    <PMID>21367529</PMID>
  </reference>
  <reference>
    <citation>Muller M, Gahankari D, Herndon DN. Operative wound management. Total burn care. 2007;3:177-195.</citation>
  </reference>
  <reference>
    <citation>Vermylen J, Verhaegen-Declercq ML, Fierens F, Verstraete M. A double blind study of the effect of tranexamic acid in essential menorrhagia. Bull Soc R Belge Gynecol Obstet. 1968;38(5):385-90.</citation>
    <PMID>4890296</PMID>
  </reference>
  <reference>
    <citation>Prentice CR. Basis of antifibrinolytic therapy. J Clin Pathol Suppl (R Coll Pathol). 1980;14:35-40. Review.</citation>
    <PMID>6159375</PMID>
  </reference>
  <reference>
    <citation>Wei W, Wei B. Comparison of topical and intravenous tranexamic acid on blood loss and transfusion rates in total hip arthroplasty. J Arthroplasty. 2014 Nov;29(11):2113-6. doi: 10.1016/j.arth.2014.07.019. Epub 2014 Jul 30.</citation>
    <PMID>25155138</PMID>
  </reference>
  <reference>
    <citation>Patatanian E, Fugate SE. Hemostatic mouthwashes in anticoagulated patients undergoing dental extraction. Ann Pharmacother. 2006 Dec;40(12):2205-10. Epub 2006 Nov 7. Review.</citation>
    <PMID>17090725</PMID>
  </reference>
  <reference>
    <citation>Mangano DT, Tudor IC, Dietzel C; Multicenter Study of Perioperative Ischemia Research Group; Ischemia Research and Education Foundation. The risk associated with aprotinin in cardiac surgery. N Engl J Med. 2006 Jan 26;354(4):353-65.</citation>
    <PMID>16436767</PMID>
  </reference>
  <reference>
    <citation>Williams-Johnson JA, McDonald AH, Strachan GG, Williams EW. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2) A randomised, placebo-controlled trial. West Indian Med J. 2010 Dec;59(6):612-24.</citation>
    <PMID>21702233</PMID>
  </reference>
  <reference>
    <citation>Jennes S, Degrave E, Despiegeleer X, Grenez O. Effect of tranexamic acid on blood loss in burn surgery: A preliminary study: 33. Journal of Burn Care &amp; Research. 2003;24:S59.</citation>
  </reference>
  <reference>
    <citation>Tang YM, Chapman TW, Brooks P. Use of tranexamic acid to reduce bleeding in burns surgery. J Plast Reconstr Aesthet Surg. 2012 May;65(5):684-6. doi: 10.1016/j.bjps.2011.09.028. Epub 2011 Oct 7.</citation>
    <PMID>21983540</PMID>
  </reference>
  <reference>
    <citation>Poeran J, Rasul R, Suzuki S, Danninger T, Mazumdar M, Opperer M, Boettner F, Memtsoudis SG. Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety. BMJ. 2014 Aug 12;349:g4829. doi: 10.1136/bmj.g4829.</citation>
    <PMID>25116268</PMID>
  </reference>
  <reference>
    <citation>Satahoo SS, Parikh PP, Naranjo D, Davis JS, Duncan RC, Pizano LR, Namias N, Schulman CI. Are burn patients really at risk for thrombotic events? J Burn Care Res. 2015 Jan-Feb;36(1):100-4. doi: 10.1097/BCR.0000000000000093.</citation>
    <PMID>25084492</PMID>
  </reference>
  <reference>
    <citation>Twisk JWR. Applied Multilevel Analysis: A Practical Guide for Medical Researchers. 2006. Cambridge University Press, London, UK.</citation>
  </reference>
  <reference>
    <citation>American Burn Association. Burn incidence fact sheet. http://www.ameriburn.org/resources_factsheet.php. Accessed May 20, 2015.</citation>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 18, 2016</study_first_submitted>
  <study_first_submitted_qc>April 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2016</study_first_posted>
  <results_first_submitted>April 23, 2021</results_first_submitted>
  <results_first_submitted_qc>August 20, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 23, 2021</results_first_posted>
  <last_update_submitted>August 20, 2021</last_update_submitted>
  <last_update_submitted_qc>August 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tranexamic Acid</keyword>
  <keyword>Burn</keyword>
  <keyword>Surgery</keyword>
  <keyword>Tangential</keyword>
  <keyword>Excision</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Burns</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 10, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/16/NCT02753816/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Enrolled participants can have multiple surgeries during the course of their stay. This is the reason for the discrepancy between the protocol enrollment and the participant flow.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Tranexamic Acid</title>
          <description>1 gram of Tranexamic Acid given over 10 minutes into the vein once prior to surgery&#xD;
Tranexamic Acid</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo given over 10 minutes into the vein once prior to surgery&#xD;
Placebo Comparator</description>
        </group>
        <group group_id="P3">
          <title>Tranexamic Acid and Placebo</title>
          <description>Patients whom received Tranexamic Acid during one surgery and Placebo in another surgery</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Tranexamic Acid</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Placebo</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Tranexamic Acid</title>
          <description>1 gram of Tranexamic Acid given over 10 minutes into the vein once prior to surgery&#xD;
Tranexamic Acid</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo given over 10 minutes into the vein once prior to surgery&#xD;
Placebo Comparator</description>
        </group>
        <group group_id="B3">
          <title>Tranexamic Acid and Placebo</title>
          <description>(see participant flow)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="7"/>
            <count group_id="B4" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="7"/>
                    <count group_id="B2" value="11"/>
                    <count group_id="B3" value="7"/>
                    <count group_id="B4" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="7"/>
                    <count group_id="B2" value="11"/>
                    <count group_id="B3" value="7"/>
                    <count group_id="B4" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.2" lower_limit="23.9" upper_limit="51.0"/>
                    <measurement group_id="B2" value="53.7" lower_limit="36.1" upper_limit="69.9"/>
                    <measurement group_id="B3" value="48.6" lower_limit="33.8" upper_limit="74.6"/>
                    <measurement group_id="B4" value="47.6" lower_limit="23.9" upper_limit="74.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="7"/>
                    <count group_id="B2" value="11"/>
                    <count group_id="B3" value="7"/>
                    <count group_id="B4" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="7"/>
                    <count group_id="B2" value="11"/>
                    <count group_id="B3" value="7"/>
                    <count group_id="B4" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Intraoperative Blood Loss in mL</title>
        <description>To determine the impact of perioperative administration of Tranexamic Acid on blood loss in major burn surgeries.</description>
        <time_frame>Intraoperative, average 122 minutes</time_frame>
        <population>1 patient in the Placebo group was excluded from this analysis. Patient was randomized to treatment but never received the treatment intraoperatively. 1 additional patient from the Placebo group was also excluded due to the missing data required to calculate intraoperative blood loss.</population>
        <group_list>
          <group group_id="O1">
            <title>Tranexamic Acid</title>
            <description>1 gram of Tranexamic Acid given over 10 minutes into the vein once prior to surgery&#xD;
Tranexamic Acid</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo given over 10 minutes into the vein once prior to surgery&#xD;
Placebo Comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Intraoperative Blood Loss in mL</title>
          <description>To determine the impact of perioperative administration of Tranexamic Acid on blood loss in major burn surgeries.</description>
          <population>1 patient in the Placebo group was excluded from this analysis. Patient was randomized to treatment but never received the treatment intraoperatively. 1 additional patient from the Placebo group was also excluded due to the missing data required to calculate intraoperative blood loss.</population>
          <units>mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="100" upper_limit="200"/>
                    <measurement group_id="O2" value="325" lower_limit="200" upper_limit="500"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Blood Transfusion Rates, Defined Nominally (Binary) as Having at Least One Transfusion</title>
        <description>To determine the impact of perioperative administration of Tranexamic Acid on transfusion rates in major burn surgeries.</description>
        <time_frame>First burn surgery to hospital discharge</time_frame>
        <population>1 patient in the Placebo group was excluded from this analysis. Patient was randomized to treatment but never received the treatment intraoperatively. 1 additional patient from the Placebo group was also excluded due the missing data required to calculate transfusion rate . 1 patient from the Tranexamic Acid group was excluded due to missing data required to calculate transfusion rate.</population>
        <group_list>
          <group group_id="O1">
            <title>Tranexamic Acid</title>
            <description>1 gram of Tranexamic Acid given over 10 minutes into the vein once prior to surgery&#xD;
Tranexamic Acid</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo given over 10 minutes into the vein once prior to surgery&#xD;
Placebo Comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Transfusion Rates, Defined Nominally (Binary) as Having at Least One Transfusion</title>
          <description>To determine the impact of perioperative administration of Tranexamic Acid on transfusion rates in major burn surgeries.</description>
          <population>1 patient in the Placebo group was excluded from this analysis. Patient was randomized to treatment but never received the treatment intraoperatively. 1 additional patient from the Placebo group was also excluded due the missing data required to calculate transfusion rate . 1 patient from the Tranexamic Acid group was excluded due to missing data required to calculate transfusion rate.</population>
          <units>Patients with 1 or more transfusions</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Tranexamic Acid on the Total Length of Hospital Admission for a Large (350 cm2) Burn Injury</title>
        <description>To determine the impact of Tranexamic Acid on total hospital length of stay by comparing the hospital admission date and the hospital discharge date. This determination will take into account current burn size and location, procedures performed and their effect on wound healing and skin graft survival.</description>
        <time_frame>Hospital admission to hospital discharge</time_frame>
        <population>For this analysis we compared patients that only received either Tranexamic Acid or Placebo. 3 patients from the Tranexamic Acid group and 2 from the Placebo group were not included in the analysis due to missing data on their length of stay.</population>
        <group_list>
          <group group_id="O1">
            <title>Tranexamic Acid</title>
            <description>1 gram of Tranexamic Acid given over 10 minutes into the vein once prior to surgery&#xD;
Tranexamic Acid</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo given over 10 minutes into the vein once prior to surgery&#xD;
Placebo Comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Tranexamic Acid on the Total Length of Hospital Admission for a Large (350 cm2) Burn Injury</title>
          <description>To determine the impact of Tranexamic Acid on total hospital length of stay by comparing the hospital admission date and the hospital discharge date. This determination will take into account current burn size and location, procedures performed and their effect on wound healing and skin graft survival.</description>
          <population>For this analysis we compared patients that only received either Tranexamic Acid or Placebo. 3 patients from the Tranexamic Acid group and 2 from the Placebo group were not included in the analysis due to missing data on their length of stay.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23" lower_limit="10" upper_limit="29"/>
                    <measurement group_id="O2" value="9" lower_limit="5" upper_limit="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Hospital admission to hospital discharge</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Tranexamic Acid</title>
          <description>1 gram of Tranexamic Acid given over 10 minutes into the vein once prior to surgery&#xD;
Tranexamic Acid</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo given over 10 minutes into the vein once prior to surgery&#xD;
Placebo Comparator</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>NSTEMI</sub_title>
                <description>suffered MI (Myocardial Infarction) one day following treatment&#xD;
- MI was determined to be &quot;Severe, Not at all related&quot;</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <description>Patient suffered an Acute Myocardial Infarction one day after study procedure</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <description>Suffered PE (Pulmonary Embolism) 3 days following treatment&#xD;
PE was determined to be &quot;Severe, Unlikely Related&quot;</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Betsy Steensma</name_or_title>
      <organization>Spectrum Health</organization>
      <phone>(616) 391-5701</phone>
      <email>elizabeth.steensma@spectrumhealth.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

